VIENNA -- July 21, 2010 -- An effective component of HIV drug regimens, abacavir has been subject to controversy following its apparent association with cardiovascular adverse events in several observational studies and in 1 randomised controlled trial (RCT). However, other RCTs and aggregated safety data contradict this.
